The epigenetics market is projected to reach USD 4.3 Billion by 2028 from USD 1.8 Billion in 2023, at a CAGR of 18.3% during the forecast period. Market growth is largely driven growing investment in research & development and rising demand for epigenetic-based therapeutics.
Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) – Global Forecast to 2028
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segment is further segmented into antibodies ChiP-sequencing kits, whole genome amplification kits, bisulfite conversion kits, 5-HMC and 5-MC analysis kits, histones, and other kits & reagents. The kits & reagents segment accounted for the largest share of the market in 2022. The highest share of the segment is owing broadening applications of chromatin immunoprecipitation (ChIP) in research studies associated with epigenetic regulatory systems and growing demand for DNA modification enzymes and histone modification enzymes.
Based on method, the epigenetics market is segmented into DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The largest share can be attributed to expanding use of DNA methylation approaches across non-oncology applications. Additionally increase in R&D to explore the role of histone modifications in oncology applications contributes to the highest CAGR recorded by the histone modifications segment in the epigenetics market.
Based on technique, the epigenetics market is divided into NGS, PCR & qPCR, mass, spectrometry, sonication, and other techniques. The NGS segment accounted for the largest share of the market in 2022. Rising demand for NGS solutions across epigenetic and mutational research studies is serving as the driving factor for growth of NGS segment.
Based on application, the epigenetics market is segmented oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications. In 2022 oncology segment accounted for the larger share of the market. The higher share of this segment is due to the growing demand for epigenetic processes such as DNA methylation and histone modification in the development of novel cancer therapeutic candidates.
Based on end user, the global epigenetics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies and hospitals & clinics. In 2022, academic & research institutes segment accounted for the largest share of the market. The key factor of driving the growth of the this market segment can be attributed to the adoption of epigenetics products across different research sectors including university laboratories and government research institutions.
Based on the region, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2022, North America accounted for the largest share of the epigenetics market, Europe is the second largest region in 2022. The growth factors can be attributed to to the robust network of epigenetic product manufacturers, and increasing NGS-based research.
The Asia Pacific market is expected to register the highest CAGR of 19.1% during the forecast period. In 2022, the growth of the market is driven by the growing pharmaceutical industry, implementation of favorable government policies and the low cost of epigenetic consumables in this region.
The epigenetics market is moderately consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode SA (US), F. Hoffmann-La Roche Ltd (Switzerland) and Epigentek Group Inc. (US) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, and agreements, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
The global epigenetics market is witnessing remarkable growth, poised to surge from $1.8 billion in 2023 to an impressive $4.3 billion by 2028, reflecting a robust compound annual growth rate (CAGR) of 18.3%. This burgeoning market is fueled by favorable government initiatives, substantial investment in epigenetic research, and an escalating demand for epigenetic-based therapeutics.
At the heart of this growth lies the quest to unravel the intricate mechanisms governing gene expression and its pivotal role in a myriad of diseases, ranging from cancer and neurological disorders to autoimmune conditions. Pharmaceutical and biotechnology giants are channeling substantial resources to decipher the complexities of epigenetic processes, harnessing their therapeutic potential to revolutionize treatment paradigms.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Notable players in this arena include industry titans such as Thermo Fisher Scientific, Illumina, PacBio, Abcam, Merck KGaA, and Bio-Rad Laboratories, among others. Their relentless pursuit of innovation is driving the integration of cutting-edge technologies, including artificial intelligence (AI) and machine learning (ML) algorithms, to unlock unprecedented insights into epigenetic patterns and their implications for disease prevention and management.
Illumina Inc (US)
In 2022 Illumina, Inc. (US) held a dominant position in the market. has successfully established a robust customer base encompassing pharmaceutical and biotechnology firms, genomic research centers, and government laboratories and hospitals. Moreover, the company enjoys a monopoly in the NGS market, providing a strategic advantage for venturing into adjacent markets such as epigenetic sequencing. For instance in 2022, Illumina, Inc. entered into an agreement with SomaLogic (US) to introduce SomaScan Proteomics Assay in high throughput next-generation sequencing (NGS) platforms manufactured by Illumina.
Thermofisher Scientific Inc (US)
Thermo Fisher Scientific (US) held the leading position in the market in 2022. The company has Strong brand image along with the diverse product portfolio. For instance in 2022, thermofisher launched the CE IVD Marked Next Generation Sequencing Instrument designed to be used in in clinical laboratories to perform both diagnostic testing and clinical research on a single instrument.
Merck KgaA (Germany)
Merck KGaA (Germany) is also one of the key player in the epigenetics market. The Life Science Research business segment of the company contributes over 45% to its 2022 revenue by providing a variety of epigenetics assays and kits. These offerings include assays for comprehensive genome-wide DNA methylation assessment as well as targeted evaluation at specific loci.
While the epigenetics market holds immense promise, it is not without its challenges. Quality concerns surrounding antibodies, the backbone of epigenetic research, pose a significant obstacle. Issues such as cross-reactivity, inconsistent sensitivity, and reproducibility threaten to undermine the accuracy and reliability of findings. Additionally, the absence of standardized validation protocols and the limited availability of well-validated antibodies for emerging epigenetic markers compound these challenges.
Nevertheless, the epigenetics market remains resilient, buoyed by the potential for transformative discoveries and driven by the relentless pursuit of knowledge. As we delve deeper into nature’s intricate code, the epigenetics revolution promises to reshape our understanding of health, disease, and the very fabric of life itself.